Vistagen therapeutics reports fiscal year 2021 financial results and provides corporate update

Palisade-1 phase 3 trial underway to evaluate ph94b for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (sad)
VTGN Ratings Summary
VTGN Quant Ranking